PMPRB has released its October 2018 NEWSletter which includes updates on Guideline Reform and PMPRB’s timelines for its Guidelines modernization initiative.

Updates on Guideline Reform

• Consultations with stakeholders have progressed more slowly than anticipated, due to conflicting views amongst participants and complexity of reforms.
• A January 2019 implementation date for the Regulations seems unlikely; PMPRB is revising the meeting schedule and timetable for the Steering Committee and Working Group.
• The PMPRB remains committed to an open and transparent consultation process as it readies itself operationally for the amended Regulations.

Other updates include:

• 2019 CPI-Based Price-Adjustment Factors for Patented Drug Products

The following table provides the CPI-Based Price-Adjustment factors for 2019. These factors were based on the actual rate of CPI inflation of 1.1% in 2015, 1.4% in 2016 and 1.6% in 2017.

The year-over-year price increase cap for the 12-month period ending December 2019 is 2.4% (=1.5 x Actual Inflation in 2017).

• NPDUIS update: Engagement activities
• New and upcoming publications
  • CompassRx, 4th edition, 2016/17
  • Market Intelligence Report on Anti-VEGF Drugs for Retinal Conditions in 2017
  • Meds Entry Watch 3^rd edition on market entry dynamics
  • Meds Pipeline Monitor (formerly New Drug Pipeline Monitor)
  • Generics360: 2017
• 2019 Human Drug Advisory Panel Meetings – Update
• Summary of the Board’s October 2018 Meeting

For more information, please see the PMPRB October 2018 NEWSletter.